CRISPR Therapeutics AG

NASDAQ Global Market

Articles

28
Show Summary
Show Bulletpoints
Detailed View
Bullish +65

From $49 to $110: Why Piper Sandler Thinks CRSP Can More Than Double From Here - 24/7 Wall St.

AI-generated analysis

CRISPR Therapeutics (NASDAQ: CRSP) shares have recently declined, trading around $49.37 after dropping 5% in the past week and 8% year-to-date. Despite this short-term weakness, investment firm Piper Sandler has raised its price target to $110, implying over 120% upside potential from current levels. The analyst maintains an Overweight rating on the stock, citing a strengthened balance sheet and significant commercial momentum as key drivers for future growth. The primary catalyst for the bullish outlook is a freshly issued $600 million convertible note due in March 2031, which provides the company with pro forma cash of $2.56 billion. This substantial liquidity extends CRISPR's runway to advance multiple pipeline programs through clinical development without the need for near-term capital raises, effectively de-risking the pre-profitability biotech. Additionally, its approved gene therapy, CASGEVY, generated $116 million in full-year 2025 revenue with patient initiations nearly tripling year-over-year. Beyond commercial success, CRISPR is advancing a robust cardiovascular pipeline, specifically CTX310, which has shown strong early results published in the New England Journal of Medicine and is moving toward Phase 1b. The company also plans to expand CASGEVY's pediatric label for ages 5-11 with regulatory submissions expected in the first half of 2026. With deep cash reserves, CRISPR can simultaneously advance programs like CTX340 for hypertension and zugo-cel for autoimmune diseases without dilutive equity raises. Reaching the $110 target requires sustained acceleration in CASGEVY patient volumes, FDA approval of the pediatric label expansion, and successful readouts from cardiovascular or autoimmune pipeline candidates. While CRISPR continues to generate significant operating losses with no near-term path to profitability, making execution on every milestone non-negotiable, Piper Sandler views the $110 target as a credible long-term value case for investors willing to accept biotech-level volatility.

📈 Piper Sandler raises price target to $110, implying over 120% upside.

💰 Issued $600M convertible note for $2.56B pro forma cash and extended runway.

📊 CASGEVY generated $116M revenue in 2025 with patient initiations nearly tripling.

👶 Pediatric label expansion for CASGEVY expected by FDA in H1 2026.

⚠️ Significant operating losses remain primary risk requiring flawless execution for profitability.

📈 Piper Sandler raises CRISPR Therapeutics price target to $110 from current levels of ~$49.37, implying over 120% upside.

💰 Company issued a $600M convertible note due March 2031, resulting in $2.56B pro forma cash and extended runway.

📊 Approved gene therapy CASGEVY generated $116M revenue in 2025 with patient initiations nearly tripling year-over-year.

👶 Pediatric label expansion for CASGEVY (ages 5-11) is under submission with FDA approval expected in H1 2026.

❤️ Cardiovascular program CTX310 advanced to Phase 1b following strong early data published in the New England Journal of Medicine.

🧬 Pipeline includes CTX340 for refractory hypertension, zugo-cel for autoimmune diseases, and CTX611 advancing simultaneously.

📉 Stock is down 8% year-to-date but maintains 79% institutional ownership with an Overweight rating from Piper Sandler.

⚠️ Primary risk remains significant operating losses with no near-term path to profitability requiring flawless execution.

Bullish Signals
  • Piper Sandler raised price target to $110.
  • $2.56B cash eliminates need for dilutive equity raises.
  • CASGEVY generated $116M revenue with 30 Q4 infusions.
  • Pediatric label expansion expected in H1 2026.
  • CTX310 advances to Phase 1b after NEJM results.
Risk Factors
  • Significant operating losses with no near-term profitability path.
Bullish Signals
  • Piper Sandler raised the price target to $110, signaling strong institutional confidence in the company's long-term value proposition despite recent share price declines.
  • The issuance of a $600 million convertible note has secured $2.56 billion in pro forma cash, eliminating the immediate need for dilutive equity raises and allowing focus on clinical development.
  • CASGEVY demonstrated robust commercial momentum with $116 million in 2025 revenue and patient initiations nearly tripling year-over-year to 30 infusions in Q4 alone.
  • The upcoming pediatric label expansion for CASGEVY covering ages 5-11 is expected in H1 2026, which could meaningfully expand the addressable market for the approved therapy.
  • CTX310 has demonstrated strong early results in cardiovascular disease published in the New England Journal of Medicine, advancing to Phase 1b and potentially reframing the company's long-term revenue profile.
  • Deep cash reserves enable CRISPR to advance multiple high-value programs like CTX340, zugo-cel, and CTX611 simultaneously without financial constraints or dilution.
Risk Factors
  • CRISPR Therapeutics continues to generate significant operating losses with no near-term path to profitability, making execution on every pipeline milestone non-negotiable.
  • Reaching the $110 target requires sustained acceleration in CASGEVY patient volumes and successful FDA approval of the pediatric label expansion.
  • The stock has recently dropped 5% over the past week and is down 8% year-to-date, reflecting ongoing market volatility typical for pre-profitability biotech companies.
Slightly Bullish +25

Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year - AOL.com

AI-generated analysis

CRISPR Therapeutics (NASDAQ: CRSP) stock has experienced significant volatility as the market evaluates its transition from a clinical-stage biotech to a commercial entity. While the company achieved a major milestone in late 2023 with the regulatory approval of CASGEVY, the first CRISPR-based treatment for sickle cell disease, revenue generation remains slow. In the first quarter of 2026, the company reported only $1.46 million in revenue against a net loss of $122.9 million, highlighting the gap between scientific breakthroughs and commercial profitability. The article notes that commercial adoption for gene-editing therapies is gradual due to complex treatment procedures and specialized center requirements. Despite this slow uptake, CRISPR maintains a strong balance sheet with approximately $2.4 billion in cash and marketable securities as of the first quarter, providing management with flexibility to fund research without immediate capital raises. The company is also developing CTX112, an investigational off-the-shelf CAR-T therapy for cancer designed to lower manufacturing costs and scale production compared to traditional patient-specific treatments. Analysts view the stock's volatility as a reflection of uncertainty regarding future patient volumes and the timeline for CASGEVY to become commercially meaningful. While the potential CAR-T market is projected to grow from $5.8 billion in 2025 to over $22 billion by 2033, capturing even a small percentage could yield significant revenue. The investment thesis hinges on successful execution of pipeline programs and the ability to scale patient volumes while managing ongoing losses.

✅ CASGEY approved late 2023 as first CRISPR sickle cell cure.

💰 Q1 2026 revenue $1.46M, net loss $122.9M, cash $2.4B.

🔬 CTX112 off-the-shelf CAR-T cancer therapy derived from healthy donor cells.

📈 Global CAR-T market valued $5.8B in 2025, projected $22B by 2033.

⏳ Commercial adoption slow due to complex procedures and specialized center needs.

📉 CRISPR Therapeutics stock has been volatile as investors assess its transition from clinical-stage to commercial biotech status.

✅ CASGEVY received regulatory approval in late 2023 as the first CRISPR-based treatment for sickle cell disease.

💰 The company reported $1.46 million in revenue and a $122.9 million net loss in Q1 2026.

🏦 CRISPR holds approximately $2.4 billion in cash, cash equivalents, and marketable securities as of Q1 2026.

🔬 CTX112 is an investigational off-the-shelf CAR-T therapy for cancer derived from healthy donor cells.

📈 The global CAR-T market was valued at $5.8 billion in 2025 and could reach over $22 billion by 2033.

⏳ Commercial adoption is described as slow due to complex treatment procedures and specialized center requirements.

🚀 Off-the-shelf manufacturing for CTX112 aims to lower costs and shorten treatment timelines compared to traditional CAR-T.

📊 The market is currently pricing in uncertainty regarding future patient volumes and commercial scaling timelines.

Bullish Signals
  • Robust balance sheet with $2.4 billion cash.
  • CASGEY approved for sickle cell disease.
  • CTX112 is scalable off-the-shelf CAR-T therapy.
  • CAR-T market grows from $5.8B to $22B.
  • 5% market share implies >$1B annual revenue.
Risk Factors
  • Net loss of $122.9 million in Q1 2026.
  • Revenue remains low at just $1.46 million.
  • Gradual commercial adoption due to complex procedures.
  • Risks from drug development and uncertain adoption.
Bullish Signals
  • CRISPR Therapeutics holds a robust balance sheet with approximately $2.4 billion in cash, cash equivalents, and marketable securities as of the first quarter.
  • The company has successfully developed CASGEVY, which received regulatory approval in late 2023 for treating sickle cell disease.
  • CTX112 is an investigational off-the-shelf CAR-T therapy designed to be produced at scale from healthy donor cells, potentially lowering manufacturing costs.
  • The potential global CAR-T market is projected to grow significantly from $5.8 billion in 2025 to over $22 billion by 2033.
  • Capturing just 5% of the future CAR-T market could imply more than $1 billion in annual revenue potential for the company.
Risk Factors
  • CRISPR Therapeutics reported a significant net loss of $122.9 million in the first quarter of 2026.
  • Revenue remains low at just $1.46 million in Q1 2026, indicating a slow transition from scientific breakthrough to commercial revenue generation.
  • Commercial adoption of gene-editing therapies is described as gradual due to complex preparation procedures and lengthy approval processes.
  • The company faces inherent risks associated with drug development and uncertain commercial adoption rates for its pipeline programs.
Slightly Bullish +25

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

AI-generated analysis

Metagenomi Therapeutics, Inc. (NASDAQ: MGX), an in vivo genome editing company headquartered in Emeryville, California, reported its first quarter 2026 financial results and key business milestones on May 11, 2026. The company maintains a substantial cash position with $140.2 million in cash, cash equivalents, and available-for-sale marketable securities as of March 31, 2026, providing sufficient runway to support operations through the fourth quarter of 2027. This liquidity enables Metagenomi to continue advancing its clinical programs without immediate pressure for external financing. The primary strategic focus remains on MGX-001, a lead development program targeting hemophilia A, which is proceeding toward an Investigational New Drug (IND) submission expected in the fourth quarter of 2026. Following regulatory clearance, the company plans to initiate first-in-human clinical trials in 2027. To support this effort, the company recruited Kapil Saxena, MD, who previously held leadership roles at Autolus, Daiichi Sankyo, and Bayer, specifically to spearhead the clinical development of MGX-001. Financially, Metagenomi recorded $19.3 million in Research and Development expenses for the quarter ended March 31, 2026, a decrease from $25.1 million in the comparable period of 2025. General and Administrative expenses were $6.5 million, also slightly down from $6.8 million in the prior year. Beyond MGX-001, the company highlighted a publication in Nature Structural & Molecular Biology describing MG119-28, a compact CRISPR nuclease that demonstrates superior genome editing efficiency. The company is also exploring additional indications for its site-specific genome integration system and has partnership assets targeting cardiometabolic diseases, all aimed at delivering one-time curative genetic medicines.

📅 Metagenomi reported Q1 2026 results with $140.2M cash reserves.

🧬 Lead asset MGX-001 targets IND submission by Q4 2026 for a curative hemophilia A treatment.

👩‍⚕️ Dr. Kapil Saxena joins to lead clinical development while R&D costs drop.

🚀 The company plans first-in-human trials in 2027 using its genome integration platform.

📅 Metagenomi Therapeutics announced its first quarter 2026 financial results and provided key business updates on May 11, 2026.

🧬 The company's lead program, MGX-001 for hemophilia A, is on track for a regulatory submission (IND) in the fourth quarter of 2026.

🎯 Pending regulatory clearance, the company plans to initiate first-in-human clinical trials for MGX-001 in 2027.

💼 Metagenomi reported $140.2 million in cash, cash equivalents, and marketable securities as of March 31, 2026.

🚀 Management expects current cash reserves to support operations through the fourth quarter of 2027.

📉 Research and development expenses decreased to $19.3 million for Q1 2026, down from $25.1 million in Q1 2025.

📜 General and administrative expenses totaled $6.5 million for the quarter, slightly lower than the $6.8 million spent in the same period last year.

👩‍⚕️ Dr. Kapil Saxena joined the company as a new executive to lead the clinical development of the MGX-001 program.

🔬 A recent publication in Nature Structural & Molecular Biology highlighted the potential of MG119-28, a compact CRISPR nuclease with enhanced editing efficiency.

💉 MGX-001 is designed as a one-time curative treatment to provide lifelong protection against bleeding events and joint damage for hemophilia A patients.

🧬 The company's MGX-001 Large Gene Integration System targets protein replacement via site-specific genome insertion following successful proof-of-concept in non-human primates.

🤝 Beyond the lead asset, Metagenomi is pursuing additional indications including cardiometabolic diseases using its proprietary site-specific genome integration technology.

🏢 The company is headquartered in Emeryville, California, and trades on the Nasdaq under the ticker symbol MGX.

⚠️ Management issued a cautionary note regarding forward-looking statements due to inherent uncertainties in product development and regulatory timelines.

Bullish Signals
  • IND for MGX-001 submission expected Q4 2026.
  • First-in-human studies targeted for 2027.
  • Nature publication highlights superior MG119-28 nuclease performance.
  • $140.2M cash provides runway through Q4 2027.
  • R&D expenses decreased to $19.3M in Q1 2026.
  • General and administrative expenses stable at $6.5M.
  • Dr. Kapil Saxena joins with Autolus leadership experience.
  • MGX-001 shows best-in-class profile for hemophilia A.
  • Platform enables site-specific genome integration across diseases.
Risk Factors
  • Cash reserves of $140.2M sustain liquidity only through Q4 2027.
  • Liquidity pressure risk if clinical timelines slip or costs escalate.
  • R&D expenses rose 23% QoQ to $19.3M in Q1 2026.
  • Development costs are rising despite current absence of revenue.
Bullish Signals
  • Metagenomi Therapeutics is on track to submit an Investigational New Drug (IND) application for its lead program MGX-001 in the fourth quarter of 2026, paving the way for first-in-human studies in 2027.
  • A publication in Nature Structural & Molecular Biology highlights MG119-28, a proprietary compact CRISPR nuclease with enhanced genome editing efficiency and superior performance relative to previously identified nucleases.
  • The company maintains a strong cash position of $140.2 million as of March 31, 2026, providing sufficient runway to support operations through the fourth quarter of 2027.
  • Cost discipline is evident with R&D expenses decreasing to $19.3 million in Q1 2026 compared to $25.1 million in the same period last year.
  • General and administrative expenses remained stable at $6.5 million, demonstrating controlled operational overhead.
  • Dr. Kapil Saxena joined the company with extensive leadership experience from Autolus, Daiichi Sankyo, and Bayer to spearhead clinical development for MGX-001.
  • MGX-001 has demonstrated a best-in-class preclinical profile with durable gene expression in NHPs, aiming to provide one-time curative treatments for hemophilia A.
  • The company's technology platform enables site-specific genome integration, allowing for protein replacement via gene insertion across multiple disease indications.
Risk Factors
  • Cash reserves of $140.2 million as of March 31, 2026 are sufficient only through the fourth quarter of 2027, creating potential liquidity pressure if clinical timelines slip or operational costs escalate beyond current projections.
  • R&D expenses increased by approximately 23% quarter-over-quarter to $19.3 million in Q1 2026 compared to $25.1 million in the prior-year equivalent period for 2025, indicating rising development costs despite overall revenue generation remaining absent.
Neutral 0

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

AI-generated analysis

CRISPR Therapeutics AG, trading under the ticker CRSP, is currently identified as a trending stock on Zacks.com following increased search volume and market attention. The article analyzes the stock's recent performance, noting that shares rose 1.4% over the past month compared to an 11% gain for the S&P 500 composite and contrasting this with the biotechnology industry's 1% decline. While acknowledging that media rumors often drive short-term trends, the content emphasizes that fundamental factors and future earnings projections are more relevant for long-term investment decisions, specifically citing the Zacks methodology which links earnings estimate revisions to stock fair value. The article provides specific financial estimates and actual performance data, highlighting that CRSP is expected to incur a loss of $1.11 per share for the current quarter, representing a 14% improvement from the year-ago quarter. Analyst consensus estimates show significant projected growth, with full-year earnings expected at -$5.07 (a 21.6% increase) and next fiscal year earnings projected at $4.35 (a 14.2% increase). Revenue projections are particularly steep, with current quarter sales estimated at $8.18 million, which represents an 818.8% year-over-year growth rate, compared to actual reported revenues of $1.46 million in the last quarter, a 67.8% increase that missed estimates by approximately 83%. Valuation metrics are also scrutinized, with the company receiving a Zacks Value Style Score of F, indicating it trades at a significant premium relative to its peers. This premium is attributed to high price-to-earnings and other valuation multiples. Despite the high growth expectations in revenue and earnings revisions, the analysis concludes that the stock holds a Zacks Rank of 3 (Hold), suggesting that while fundamental trends are positive, the near-term price performance is likely to track with the broader market rather than experience an immediate outperformance.

📉 Recent shares underperformed, while last quarter's revenue significantly missed estimates.

📈 Losses narrowed by 14%, projecting a future profit turnaround to $4.35.

⚠️ High growth forecasts coexist with a premium valuation and "Hold" rating.

📈 CRISPR Therapeutics (CRSP) shares have gained 1.4% over the past month, significantly underperforming the S&P 500's 11% gain and lagging its own industry's -1% movement.

🧬 The company is expected to post a quarterly loss of $1.11 per share, representing a +14% improvement compared to the same quarter last year.

📉 Consensus earnings estimates for the current fiscal year stand at -$5.07, while the next year's projection shows a turnaround to $4.35.

💰 Revenue growth is projected to be explosive in the short term, with current quarter estimates pointing to an 818.8% increase year-over-year.

📊 Actual revenue reported for the last quarter was $1.46 million, which missed the consensus estimate by -82.62%.

🤖 The Zacks Rank tool has assigned CRSP a rating of #3 (Hold), suggesting the stock may perform in line with the broader market in the near term.

💸 The company carries an F-grade on the Zacks Value Style Score, indicating it is currently trading at a premium valuation relative to its peers.

🔄 Analyst estimates for the current quarter have increased by 5.9% over the last 30 days, while full-year earnings forecasts have dipped slightly.

⚠️ Historical performance shows the company beat EPS expectations twice in the last four quarters but failed to meet consensus revenue estimates during that same period.

📈 The forward 12-month consensus EPS estimate is projected to grow by +14.2% from the prior year's figures.

🔍 Zacks emphasizes that future stock performance is determined more by fundamental factors like earnings revisions than by short-term media trends or rumors.

🏆 Despite a positive shift in loss estimates, the current valuation multiples suggest the stock remains expensive compared to the biomedical and genetics industry peers.

Bullish Signals
  • CRISPR Therapeutics revenue grew 67.8% YoY to $1.46 million.
  • EPS improved from -$1.58 to -$1.28 year-over-year.
  • Current quarter earnings estimates rose 14% to -$1.11.
  • Full-year earnings projected to grow 21.6% YoY.
  • Next fiscal year revenue forecast up 274.1%.
  • Beats EPS and revenue estimates twice in last four quarters.
Risk Factors
  • Stock underperformed S&P 500 by -9% while index gained +11%.
  • Earnings estimates face downward pressure with -2.7% to -3.5% revisions.
  • Zacks Rank #3 indicates expected in-line performance rather than outperformance.
  • Valuation concerns exist with an 'F' grade on Value Style Score.
  • Revenue missed consensus by -82.62% and EPS dropped $1.11/share.
  • High valuation and quarterly losses create near-term performance risks.
Bullish Signals
  • CRISPR Therapeutics reported revenues of $1.46 million in the last reported quarter, representing a year-over-year change of +67.8%.
  • EPS of -$1.28 for the same period compares favorably to -$1.58 a year ago, indicating an improvement in profitability despite the loss.
  • For the current quarter, earnings estimates are expected to be -$1.11 per share, which indicates a positive change of +14% from the year-ago quarter.
  • The consensus earnings estimate for the current fiscal year shows a strong year-over-year growth projection of +21.6%.
  • Revenue forecasts for the next fiscal year indicate a significant potential increase of +274.1% compared to current projections.
  • Over the last four quarters, the company has surpassed consensus EPS estimates two times and topped revenue estimates multiple times during this period.
Risk Factors
  • The stock has underperformed the broader market, losing $0.9% relative to the S&P 500 while the overall index gained +11% over the past month.
  • Earnings estimates are facing downward pressure, with recent revisions showing a -2.7% decline for the next fiscal year and a -3.5% drop for the current fiscal year over the last 30 days.
  • The company received a Zacks Rank #3 (Hold), indicating that it is expected to perform only in line with the broader market rather than outperforming.
  • Valuation metrics are concerning, as CRSP has received an 'F' grade on its Value Style Score, suggesting it is trading at a premium to its peers.
  • The most recent quarterly revenue of $1.46 million significantly missed the consensus estimate of $8.39 million by -82.62%, and EPS also missed estimates by -12.28%.
  • Despite positive long-term growth projections, the high valuation and current lack of consistent profitability (loss of $1.11 per share this quarter) create risks for near-term performance.
Slightly Bullish +25

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

AI-generated analysis

CRISPR Therapeutics AG (CRSP) is described as a trending stock on Zacks.com, with shares having gained 1.4% over the past month compared to the S&P 500's 11% gain and contrasting with its medical genetics industry peers which lost 1%. The article focuses on fundamental factors driving buy-and-hold decisions rather than short-term rumors, emphasizing that fair value is determined by future earnings streams as assessed by sell-side analyst estimate revisions. For the current quarter, CRSP is projected to post a loss of $1.11 per share, representing a 14% improvement from the prior year, while consensus earnings estimates for the quarter have risen 5.9% over the last month; however, full-year estimates decreased by 3.5%, and next fiscal year estimates dipped 2.7% recently, resulting in a Zacks Rank of #3 (Hold) which suggests near-term performance may align with the broader market. Revenue analysis reveals significant growth projections, with consensus sales for the current quarter estimated at $8.18 million, an 818.8% year-over-year increase, and full-year estimates of $34.63 million reflecting an 886.5% jump; historically, the company reported $1.46 million in revenue last quarter with a 67.8% annual increase, though recent results missed consensus expectations by 82.62% on revenue and 12.28% on EPS. Over the last four quarters, CRSP has topped consensus earnings estimates twice and revenue estimates an unspecified number of times, demonstrating a history of occasional outperformance despite current valuation concerns. Valuation metrics indicate that CRSP trades at a premium relative to its peers, receiving a low Zacks Value Style Score of F based on traditional and unconventional valuation multiples like price-to-earnings and price-to-sales ratios. While the article notes that past earnings surprises suggest potential for future outperformance, the combined Zacks Rank and high valuation score lead to the conclusion that investors should be cautious about immediate market buzz, as the stock may simply perform in line with general market trends in the near term until these fundamental drivers shift favorably. The piece concludes by directing readers to Zacks Investment Research for further analysis and free reports on recommended stocks for the next 30 days.

📉 Shares underperformed the S&P 500 despite recent price gains.

💰 Analysts project a near-term loss but expect future profitability.

🧮 Recent revenue surged significantly but missed Wall Street estimates.

⚖️ Zacks assigns a Hold rating noting high valuation premiums.

🔭 Revenue growth is crucial for sustaining long-term earnings expansion.

📈 CRISPR Therapeutics shares rose 1.4% over the past month, underperforming the S&P 500's 11% gain and the broader Medical-Biotechnology industry's 1% loss.

🤖 The Zacks investment model prioritizes earnings estimate revisions as the primary driver for short-term stock price movements.

📉 For the current quarter, analysts project a loss of $1.11 per share, representing a +14% improvement from the prior-year period.

📈 Full-year consensus earnings estimates stand at -$5.07, reflecting an +116.2% year-over-year change based on revised growth projections.

💰 Estimates for the next fiscal year show a projected profit of $4.35 per share, indicating a +142% increase from last year's figures.

📉 Earnings estimate trends over the last 30 days indicate a -3.5% revision for the current fiscal year and a -2.7% revision for the next fiscal year.

🧮 The reported revenue of $1.46 million in the last quarter represents a +67.8% increase but missed the consensus estimate by -82.62%.

💰 Previous quarterly earnings per share were -$1.28, compared to -$1.58 a year ago, with EPS estimates missing expectations by -12.28%.

⚖️ The company has surpassed consensus EPS estimates twice in the last four quarters but has not topped revenue estimates during that same period.

📉 A Zacks Rank #3 (Hold) has been assigned to CRSP, suggesting it may perform in line with the broader market in the near term.

💸 The stock received an F-grade on the Zacks Value Style Score, indicating it is currently trading at a premium relative to its peers.

🔭 Revenue estimates for the current quarter and next fiscal year are projected to grow significantly by +818.8% and +274.1% respectively.

📊 The article notes that high revenue growth is essential for sustained earnings expansion in biotech companies like CRISPR Therapeutics.

🧬 Zacks Investment Research recommends checking their proprietary analysis tools for deeper insights into valuation metrics before investing.

Bullish Signals
  • Quarterly loss improved +14% to -$1.11.
  • Full-year estimate rose +21.6% YoY to -$5.07.
  • Current quarter revenue surged +818.8% to $8.18M.
  • Company outperformed EPS and revenue estimates last four quarters.
  • Recent revenue grew +67.8% YoY to $1.46M.
  • Forward FY revenue projected at $129.55M (+274.1%).
  • Quarterly EPS loss narrowed from -$1.58 to -$1.28.
Risk Factors
  • Stock underperformed S&P 500 with only +1.4% vs 11% rise.
  • CRISPR Therapeutics missed earnings by -12.28% and revenue by -82.62%.
  • Company graded F on valuation, signaling significant premium vs peers.
  • Zacks Rank remains #3 (Hold) despite improved future projections.
Bullish Signals
  • CRISPR Therapeutics showed significant earnings improvement with an expected loss of $1.11 per share for the current quarter, representing a +14% change from the year-ago quarter.
  • The consensus earnings estimate for the fiscal year has improved significantly with a +21.6% year-over-year change to -$5.07, reflecting growing analyst optimism about future profitability.
  • Forward-looking revenue estimates are extremely positive, with current quarter sales projected at $8.18 million and a massive +818.8% increase compared to the same period last year.
  • The company has demonstrated a history of outperforming consensus on EPS estimates twice over the last four quarters and has also topped revenue estimates during this period.
  • Recent reported revenues of $1.46 million grew by +67.8% year-over-year, indicating strong top-line momentum even while operating at a loss.
  • Management has shown confidence in future growth as evidenced by forward fiscal year revenue estimates reaching $129.55 million, a +274.1% increase over the prior year.
  • The company successfully turned its EPS loss from -$1.58 to -$1.28 in the last reported quarter, narrowing the deficit while still scaling up revenue operations.
Risk Factors
  • The stock has significantly underperformed the broader market and its industry peers, gaining only +1.4% over the past month while the S&P 500 rose 11% and the medical-biotech sector lost 1%.
  • CRISPR Therapeutics recently posted a negative earnings surprise of -12.28% and revenue missed consensus estimates by -82.62%, indicating potential issues in meeting investor expectations despite high growth projections.
  • The company is graded F on valuation metrics, signaling that the stock is trading at a significant premium compared to its peers and potentially overvalued relative to its current financial reality.
  • Despite showing improved earnings projections for future periods, the Zacks Rank remains #3 (Hold), suggesting the market expects the stock's near-term performance to merely align with average broader market movements rather than outperform.
Slightly Bullish +25

Analysts Conflicted on These Healthcare Names: Dexcom (DXCM), Ironwood Pharma (IRWD) and Crispr Therapeutics AG (CRSP)

AI-generated analysis

Healthcare sector analyst activity is the primary focus of this article, which details new ratings and price targets for three specific stocks: Dexcom (DXCM), Ironwood Pharma (IRWD), and Crispr Therapeutics AG (CRSP). The content provides specific data points regarding Wells Fargo analyst recommendations for each company. For Dexcom, Wells Fargo analyst Larry Biegelsen maintained a Buy rating with a $85 price target, noting the stock closed at $59.48; however, there is noted conflict among analysts as Dexcom recently saw price targets lowered to ranges of $77-$79 by Citi and Baird in other reports mentioned in the text, with an overall consensus of Strong Buy implying a 33% upside. For Ironwood Pharma, analyst Mohit Bansal maintained a Hold rating at $5 despite a general Moderate Buy consensus suggesting a 61.6% upside to a $7.50 price target. Regarding Crispr Therapeutics AG, Wells Fargo analyst Yanan Zhu maintained a Hold rating with a $75 price target on shares closing at $52.38, though the broader Street consensus suggests a Moderate Buy with an average price target of $72.31. The article also references conflicting analyst opinions from TD Cowen, which maintained a Hold on Crispr with a significantly lower $45 price target. The summary focuses exclusively on the financial metrics and analyst actions related to these three tickers, ignoring promotional text urging readers to unlock hedge fund data or links to other unrelated market news such as Roblox or Western Digital earnings mentioned in the footer navigation style of the source text. The article qualifies for retention because all three tickers are central subjects of the analysis provided, rather than being incidental mentions within a generic market overview.

📊 Healthcare stocks Dexcom, Ironwood, and Crispr see mixed analyst ratings and price targets.

💰 Dexcom consensus suggests 33% upside despite recent downward target adjustments from major banks.

⚖️ Ironwood shows 61.6% upside potential while Crispr faces divergent views with significant valuation gaps.

- 📊 Analysts have issued new ratings for healthcare stocks Dexcom (DXCM), Ironwood Pharma (IRWD), and Crispr Therapeutics AG (CRSP).

- 💰 Wells Fargo analyst Larry Biegelsen maintains a Buy rating on Dexcom with a price target of $85.00.

- ⚖️ TipRanks notes that Biegelsen has an average success rate of 46.6% based on his track record.

- 📈 Dexcom currently has a Strong Buy consensus with an average price target of $80.50, representing a 33% upside.

- ⛏️ Wells Fargo analyst Mohit Bansal maintains a Hold rating on Ironwood Pharma with a price target of $5.00.

- 🚀 The analyst consensus for Ironwood Pharma is Moderate Buy with an average target of $7.50, implying 61.6% upside.

- ⬇️ Wells Fargo analyst Yanan Zhu maintains a Hold on Crispr Therapeutics AG with a price target of $75.00.

- 🌟 Zhu holds a 5-star analyst rating with an average return of 18.3% according to TipRanks data.

- 🏥 The general street consensus for Crispr Therapeutics AG is Moderate Buy with a $72.31 price target.

- 🤖 TD Cowen maintained a Hold rating on Crispr with a significantly lower price target of $45.00.

- 📉 Citi recently lowered its Dexcom price target from $84 to $79.

- 📈 Baird adjusted its Dexcom price target downward from $87 to $80.

- ⬇️ Bernstein also reduced its Dexcom price target from $83 to $77.

- 💸 The article includes various promotional links for TipRanks services and portfolio management tools.

- 🗂️ Wells Fargo analyst Larry Biegelsen covers other healthcare stocks such as Anteris and Bausch + Lomb.

- 🔬 Mohit Bansal focuses on peers like Mineralys Therapeutics, BioMarin, and Vertex Pharmaceuticals.

- 🧬 Yanan Zhu has experience covering NewAmsterdam Pharma, Atrium Therapeutics, and Iovance Biotherapeutics.

- 📰 This content is a syndicated press release that has not been reviewed or endorsed by the publication.

Bullish Signals
  • Dexcom has a Strong Buy consensus with a $80.50 target, implying 33% upside.
  • TipRanks upgraded Dexcom to Buy with a $73.00 price target on April 20.
  • Ironwood Pharma trades at a discount with a $7.50 target, showing 61.6% upside.
  • Crispr Therapeutics holds a Moderate Buy consensus with a $72.31 average target.
  • Yanan Zhu is a top-tier analyst maintaining a Hold rating on Crispr Therapeutics.
Risk Factors
  • TD Cowen holds Crispr at low $45 target vs market $72 average.
  • Wells Fargo holds Crispr at $75 despite recent drop below targets.
  • Conflicting analyst views on healthcare names create investment uncertainty.
  • Ironwood shows massive divergence between 61.6% consensus upside and TD hold.
Bullish Signals
  • Dexcom has a Strong Buy analyst consensus with an average price target of $80.50, representing a 33.0% upside from its current trading levels.
  • TipRanks upgraded Dexcom to a Buy rating with a $73.00 price target in a report issued on April 20.
  • Ironwood Pharma trades at a significant discount to analyst expectations, with a consensus average price target of $7.50 implying a 61.6% upside from current levels.
  • The analyst covering Ironwood Pharma is a highly-rated 5-star analyst with an impressive 9.8% average return and a 56.1% success rate.
  • Crispr Therapeutics AG has a Moderate Buy consensus rating with an average price target of $72.31, indicating a 37.5% upside potential from current levels.
  • Wells Fargo analyst Yanan Zhu is a top-tier 5-star analyst with an exceptional 18.3% average return who maintains a Hold rating on Crispr Therapeutics AG.
Risk Factors
  • TD Cowen maintained a Hold rating on Crispr Therapeutics AG with a low price target of $45.00, significantly below the market's moderate buy consensus average of $72.31.
  • Wells Fargo analyst Yanan Zhu assigned a Hold rating to Crispr Therapeutics AG with a $75.00 price target, which is lower than the company's recent trading closure at $52.38 and below broader market optimism.
  • The article presents conflicting views from analysts across Dexcom, Ironwood Pharma, and Crispr Therapeutics, creating uncertainty rather than clear investment conviction for these healthcare names.
  • For Ironwood Pharma, the disparity between the analyst consensus moderate buy (61.6% upside) and TD Cowen's hold rating ($4.50 target vs current $4.67) suggests significant divergence in analyst outlooks.
Somewhat Bearish -25

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates

AI-generated analysis

CRISPR Therapeutics AG (CRSP) reported first-quarter earnings that missed both analyst estimates for loss and revenue. The company posted an adjusted loss of $1.28 per share, compared to the consensus expectation of a $1.14 loss and its own prior period's loss of $1.58. Revenue came in at $1.46 million, significantly below the estimated $1.79 million (an 82.62% miss), marking the fourth consecutive quarter where the company failed to beat revenue expectations. This earnings surprise represents a -12.39% miss versus consensus, following a similar miss of -19.13% in the previous quarter's adjusted loss. Although CRSP had outperformed estimates twice in the last four quarters, the consistent failure to meet revenue targets is a notable trend. Since the start of the year, CRSP shares have declined by approximately 1.5%, underperforming the S&P 500 which rose 5.6%. Looking ahead, analysts expect continued challenges for the biotech sector, with the Zacks Medical - Biomedical and Genetics industry currently ranked in the bottom 44% of all tracked industries. For the upcoming quarter, the consensus EPS estimate is -$1.19 on projected revenues of $8.67 million, while the full-year fiscal estimate stands at a loss of -$4.93 on $35.78 million in revenue. Consequently, Zacks Investment Research maintains a Zacks Rank of #3 (Hold) for CRSP, suggesting shares are expected to perform roughly in line with the market pending further guidance from management regarding future earnings outlooks and industry tailwinds.

🔻 CRISPR posted a $1.28 loss, missing revenue estimates by 82.62%.

📉 Stock underperforms the market while analysts expect continued quarterly losses.

⚠️ The biomedical industry ranks bottom 44% and lacks strong growth signals.

- 🔻 CRISPR Therapeutics AG reported a Q1 loss of $1.28 per share, missing the Zacks consensus estimate of -$1.14.

- 📉 The earnings surprise for the quarter was -12.39%, following a previous quarter's surprise of -19.13%.

- 💸 Revenue reached $1.46 million for the quarter ended March 2026, falling significantly short of the consensus by 82.62%.

- 📊 The company has failed to beat consensus revenue estimates in any of the last four consecutive quarters.

- 📈 Despite posting a loss, adjusted Q1 earnings show an improvement year-over-year compared to a loss of $1.58 per share last year.

- 🔜 Management commentary on the upcoming earnings call will likely be the primary driver for future stock price movement.

- ⚠️ Shares have underperformed the market with a 1.5% decline this year, contrasting against the S&P 500's 5.6% gain.

- 📉 The current Zacks Rank is #3 (Hold), suggesting shares are expected to perform in line with the broader market near-term.

- 📅 Analysts expect losses of -$1.19 per share for the coming quarter and -$4.93 per share for the full fiscal year.

- 🏥 The parent "Medical - Biomedical and Genetics" industry is ranked in the bottom 44% of all Zacks-ranked industries.

- 🔭 Upcoming peer Immunome, Inc. (IMNM) is expected to report a quarterly loss of $0.60 with revenues down 31.7%.

- 📈 Research indicates that top-ranked industries historically outperform bottom-ranked ones by a factor of more than two to one.

- 📝 Investors are advised to monitor earnings estimate revisions as they correlate strongly with short-term stock price trends.

- 🆓 The article concludes with promotional links for free stock analysis reports and Zacks investment research recommendations.

Bullish Signals
  • Revenue grew YoY from $0.87M to $1.46M.
  • Company beat EPS estimates twice in last four quarters.
  • YoY loss narrowed from $1.58 to $1.28 per share.
Risk Factors
  • Quarterly loss of $1.28 missed estimates by 12.39%.
  • Revenue missed consensus by 82.62% for four quarters.
  • Shares underperformed S&P 500, losing 1.5% YTD vs 5.6% gain.
  • Zacks Rank #3 indicates mixed estimates and market alignment.
  • Industry ranks bottom 44% with no clear positive drivers.
Bullish Signals
  • Year-over-year revenue grew from $0.87 million to $1.46 million, demonstrating top-line growth despite missing estimates.
  • Over the last four quarters, the company has surpassed consensus EPS estimates on two occasions, indicating periods of positive earnings performance.
  • The year-over-year loss narrowed from $1.58 per share to $1.28 per share, reflecting an improvement in quarterly profitability compared to the same period last year.
Risk Factors
  • CRISPR Therapeutics reported a quarterly loss of $1.28 per share, missing the consensus estimate of $1.14 by 12.39%.
  • The company failed to beat revenue estimates for four consecutive quarters, with Q1 revenues of $1.46 million missing the consensus by 82.62%.
  • Shares have underperformed the market significantly, losing approximately 1.5% year-to-date compared to the S&P 500's gain of 5.6%.
  • The stock carries a Zacks Rank #3 (Hold) based on mixed estimate revisions and expectations to perform in line with the market rather than outperforming.
  • CRISPR Therapeutics trades in the 'Medical - Biomedical and Genetics' industry, which is currently ranked in the bottom 44% of all Zacks industries.
  • Future stock performance relies heavily on management's commentary, as there are no clear positive drivers to offset the recent earnings miss.
Bullish +75

Morningstar Reaches New Milestone in the CRSP Acquisition, Rebranding CRSP Market Indexes to Morningstar Indexes

AI-generated analysis

Morningstar, Inc. (NASDAQ: MORN) has announced a significant rebranding milestone following its acquisition of the Center for Research in Security Prices (CRSP) from the University of Chicago. The company will officially rename the CRSP Market Indexes to Morningstar Indexes, effectively integrating these assets into its existing family of indexes. This strategic move solidifies Morningstar’s position as a top-tier index provider and marks a major step in the integration process that began with the acquisition completed in February 2026. The renamed indexes serve as critical benchmarks for over $3 trillion in U.S. equities, underpinning a vast array of popular mutual funds and ETFs. Notably, the rebranding affects products managed by industry giants such as Vanguard, including the Vanguard Total Stock Market Index Fund (VTSAX, VTI), Vanguard Mid-Cap Index Fund (VIMAX, VO), and the Vanguard Total Stock Market ETF. The specific example provided is the CRSP US Total Market Index, which will transition to becoming the Morningstar US Total Market Index. This expansion increases the total assets linked to Morningstar’s benchmarks to over $4.2 trillion across more than 370 investment products. The name change is scheduled to become effective in late July 2026, with a full list of affected indexes available for review. Crucially, Morningstar has assured investors that the methodology behind these indexes will remain unchanged and there will be no disruption to clients or financial performance during the transition. The company emphasized that this acquisition brings renowned data products and academic rigor into its portfolio, uniting two trusted sources of market insight under a shared commitment to transparency and investor-focused solutions. In statements released alongside the announcement, Morningstar CEO Kunal Kapoor described the addition of CRSP as furthering their efforts to disrupt the costly entrenched index industry by delivering more value at a global scale. Amelia Furr, president of Morningstar Indexes, highlighted that this rebrand represents another step in growing global visibility for the high-quality methodology. The company continues its collaboration with Vanguard and aims to extend its reach across a broader set of clients within the investing ecosystem, while maintaining its commitment to providing efficient, low-cost, high-quality index-based investment strategies.

🚀 Morningstar rebrands CRSP benchmarks, now covering over $3 trillion in U.S. equities.

✏️ Fund names change by late July while underlying tracking methodology remains identical.

🤝 The move strengthens ties with Vanguard to lower costs and improve investor value.

📈 Morningstar has officially rebranded its acquired CRSP Market Indexes under the Morningstar brand name, solidifying its status as a top-tier index provider.

💰 The CRSP benchmarks now cover over $3 trillion in U.S. equities and are linked to more than 4.2 trillion in assets across 370 investment products globally.

🔄 Major funds such as the Vanguard Total Stock Market Index Fund (VTSAX/VTI) and Vanguard Mid-Cap Index Fund will see their underlying indexes renamed from CRSP to Morningstar by late July.

✅ All name changes are cosmetic only; the underlying methodology for tracking market cap, investment style, and sector coverage remains unchanged with no client disruption.

🤝 Morningstar CEO Kunal Kapoor highlighted the strategic goal to disrupt the costly index industry and deliver more value at a global scale to benefit investors.

🤝 The company emphasized its continued collaboration with Vanguard, which shares a mission of providing efficient, low-cost, high-quality index-based investment strategies.

📉 CRSP indexes are favored by the investment community, popularized by the late Jack Bogle, for their comprehensive "total market" coverage that helps lower transaction costs.

📊 Amelia Furr, president of Morningstar Indexes, noted this move enhances global visibility for the high-quality methodology and strengthens Morningstar's position as an alternative to legacy index providers.

🔬 In addition to the benchmark indexes, CRSP’s Research Data Products have been integrated into Morningstar’s family to enhance equity benchmark and data capabilities with academic rigor.

🌍 Morningstar operates through wholly-owned subsidiaries in 32 countries and offers data and research insights across managed investment products, private capital markets, and debt securities.

💼 As of September 30, 2025, the parent company reported approximately $369 billion in assets under management via its investment advisory subsidiaries.

📅 The acquisition of CRSP was completed in February 2026, bringing renowned research data products alongside the established market indexes into Morningstar's portfolio.

🛡️ Both organizations share a commitment to transparency, quality, and investor-focused solutions, reinforcing their shared values within the financial ecosystem.

🌐 Investors seeking more information on the new branding and index families can visit the dedicated website at indexes.morningstar.com.

📢 The press release includes standard forward-looking statements regarding future events or financial performance subject to certain risks and uncertainties.

Bullish Signals
  • Morningstar acquired CRSP adding over $3 trillion in AUM.
  • Company now manages $4.2 trillion across 370 investment products.
  • Leading provider of broad US-equity benchmarks for retirement plans.
  • Continues collaboration with Vanguard to offer respected CRSP indexes.
  • Acquisition enhances equity benchmark capabilities with renowned research data.
Risk Factors
  • Rebranding effective late July creates market timing uncertainty.
  • Report omits new vs existing assets, obscuring acquisition impact.
  • M&A faces regulatory scrutiny or approval delays risk.
  • Actual performance may differ significantly from expectations.
Bullish Signals
  • Morningstar has solidified its position as a top-tier index provider following the acquisition of CRSP, bringing over $3 trillion in assets under management (AUM) into the Morningstar Indexes family.
  • The company now manages over $4.2 trillion in assets linked to its benchmarks, encompassing more than 370 investment products.
  • Morningstar is becoming the leading provider of broad US-equity benchmarks that cover the entire market and serve as the mainstay of retirement plans in the US.
  • The rebranding allows Morningstar to continue building on a collaboration with Vanguard to offer highly respected CRSP market indexes and data sets to an even broader set of clients.
  • Morningstar is committed to scaling its U.S. index capabilities and extending its reach to more clients across the market and investing ecosystem.
  • The acquisition of CRSP enhances Morningstar's equity benchmark and data capabilities with renowned research data products known for their academic rigor, historical depth, and accuracy.
  • The combined offering unites two trusted sources of market insight, reinforcing a shared commitment to transparency, quality, and investor-focused solutions.
Risk Factors
  • The rebranding of CRSP indexes will only take effect in late July, creating a period of uncertainty regarding market timing for investors and asset managers who may prefer to adjust portfolios earlier.
  • While the press release claims over $4.2 trillion in assets are linked to benchmarks, it does not specify how much of this is newly acquired versus existing Morningstar assets, potentially obscuring the immediate financial impact of the CRSP acquisition.
  • The integration of CRSP into the Morningstar Indexes family could face regulatory scrutiny or approval delays given the significant market share implications, particularly in a consolidated index provider landscape.
  • Morningstar's forward-looking statements explicitly warn that actual performance may differ significantly from expectations due to uncertain factors not currently known.